AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.
Company profile
Ticker
AVEO
Exchange
Website
CEO
Michael Bailey
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AVEO PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
AVEO Pharma Limited • AVEO Securities Corporation • AVEO Pharma (Ireland) Limited Ireland ...
AVEO stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
30 Jan 23
EFFECT
Notice of effectiveness
24 Jan 23
EFFECT
Notice of effectiveness
24 Jan 23
EFFECT
Notice of effectiveness
24 Jan 23
25-NSE
Exchange delisting
19 Jan 23
POS AM
Prospectus update (post-effective amendment)
19 Jan 23
POS AM
Prospectus update (post-effective amendment)
19 Jan 23
POS AM
Prospectus update (post-effective amendment)
19 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jan 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 77.40 mm | 77.40 mm | 77.40 mm | 77.40 mm | 77.40 mm | 77.40 mm |
Cash burn (monthly) | (no burn) | (no burn) | 722.67 k | 2.04 mm | (no burn) | 1.89 mm |
Cash used (since last report) | n/a | n/a | 13.66 mm | 38.57 mm | n/a | 35.69 mm |
Cash remaining | n/a | n/a | 63.74 mm | 38.83 mm | n/a | 41.71 mm |
Runway (months of cash) | n/a | n/a | 88.2 | 19.0 | n/a | 22.1 |
Institutional ownership, Q1 2023
18.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 110 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 28.42 mm |
Total shares | 6.34 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Growth Equity Opportunities Fund IV | 5.42 mm | $28.42 mm |
Hirschman Orin | 920.36 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Jan 23 | Michael P Bailey | Common Stock | Sale back to company | Dispose D | No | No | 15 | 333,167 | 5.00 mm | 0 |
19 Jan 23 | Michael P Bailey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.67 | 625,192 | 2.29 mm | 0 |
19 Jan 23 | Michael P Bailey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.12 | 275,100 | 2.51 mm | 0 |
19 Jan 23 | Michael P Bailey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.6 | 35,302 | 197.69 k | 0 |
19 Jan 23 | Michael P Bailey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.2 | 93,500 | 579.70 k | 0 |
19 Jan 23 | Michael P Bailey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 15.7 | 16,750 | 262.98 k | 0 |
19 Jan 23 | Michael P Bailey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 30.8 | 99,999 | 3.08 mm | 0 |
19 Jan 23 | Michael P Bailey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6 | 75,366 | 452.20 k | 0 |
19 Jan 23 | Michael P Bailey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 10.8 | 46,000 | 496.80 k | 0 |
19 Jan 23 | Michael P Bailey | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 8.4 | 90,000 | 756.00 k | 0 |